EA200501699A1 - Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин - Google Patents

Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин

Info

Publication number
EA200501699A1
EA200501699A1 EA200501699A EA200501699A EA200501699A1 EA 200501699 A1 EA200501699 A1 EA 200501699A1 EA 200501699 A EA200501699 A EA 200501699A EA 200501699 A EA200501699 A EA 200501699A EA 200501699 A1 EA200501699 A1 EA 200501699A1
Authority
EA
Eurasian Patent Office
Prior art keywords
serum albumin
human serum
liquid compositions
containing human
stabilized interferon
Prior art date
Application number
EA200501699A
Other languages
English (en)
Other versions
EA009995B1 (ru
Inventor
Фабрицио Самаритани
Алессандра Дель Рио
Original Assignee
Арес Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арес Трейдинг С.А. filed Critical Арес Трейдинг С.А.
Publication of EA200501699A1 publication Critical patent/EA200501699A1/ru
Publication of EA009995B1 publication Critical patent/EA009995B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описана стабилизированная не содержащая ЧСА жидкая фармацевтическая композиция интерферона (IFN), где препарат представляет собой раствор, содержащий буфер, поверхностно-активное вещество, агент, придающий изотоничность и антиоксидант. Предпочтительно, интерферон представляет собой человеческий рекомбинантный IFN-бета.
EA200501699A 2003-05-01 2004-04-29 Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин EA009995B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03101210 2003-05-01
US53016903P 2003-12-17 2003-12-17
PCT/EP2004/004806 WO2004096263A2 (en) 2003-05-01 2004-04-29 Human serum albumin-free stabilized interferon liquid formulations

Publications (2)

Publication Number Publication Date
EA200501699A1 true EA200501699A1 (ru) 2006-06-30
EA009995B1 EA009995B1 (ru) 2008-06-30

Family

ID=36908159

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200800327A EA200800327A1 (ru) 2003-05-01 2004-04-29 Стабилизированные жидкие композиции интерферона, не содержащие человеческий сыворотный альбумин
EA200501699A EA009995B1 (ru) 2003-05-01 2004-04-29 Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200800327A EA200800327A1 (ru) 2003-05-01 2004-04-29 Стабилизированные жидкие композиции интерферона, не содержащие человеческий сыворотный альбумин

Country Status (29)

Country Link
US (1) US8309069B2 (ru)
EP (1) EP1617861B1 (ru)
JP (2) JP4870550B2 (ru)
KR (1) KR101116058B1 (ru)
CN (1) CN1816347B (ru)
AR (1) AR044147A1 (ru)
AU (2) AU2004233603B2 (ru)
BR (1) BRPI0410488B8 (ru)
CA (1) CA2521560A1 (ru)
DK (1) DK1617861T3 (ru)
EA (2) EA200800327A1 (ru)
ES (1) ES2417061T3 (ru)
HK (1) HK1088847A1 (ru)
HR (1) HRP20130512T1 (ru)
IL (1) IL171709A (ru)
ME (1) ME00404B (ru)
MX (1) MXPA05011718A (ru)
MY (1) MY151121A (ru)
NO (1) NO335674B1 (ru)
NZ (2) NZ566625A (ru)
PL (1) PL1617861T3 (ru)
PT (1) PT1617861E (ru)
RS (1) RS52869B (ru)
SG (1) SG159389A1 (ru)
SI (1) SI1617861T1 (ru)
TW (1) TWI272948B (ru)
UA (2) UA80331C2 (ru)
WO (1) WO2004096263A2 (ru)
ZA (2) ZA200508124B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2547822A1 (en) * 2003-12-11 2005-06-30 Ares Trading S.A. Stabilized interferon liquid formulations
JP2007538048A (ja) * 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
JP4988562B2 (ja) * 2004-06-01 2012-08-01 アレス トレーディング ソシエテ アノニム 安定化したインターフェロン液体製剤
DK1951395T3 (da) * 2005-09-14 2012-04-02 Ares Trading Sa Fremgangsmåde til kvantitativ bestemmelse af poloxamerer
US9925151B2 (en) 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
WO2008066322A1 (en) * 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
JPWO2008065752A1 (ja) * 2006-11-30 2010-03-04 国立大学法人北海道大学 ｄｉＲＮＡを有効成分とする免疫治療用薬剤
LT2134353T (lt) 2007-03-30 2017-03-27 Xisle Pharma Ventures Trust Dvifazė lipidų vezikulių kompozicija ir gimdos kaklelio displazijos gydymo būdas, skiriant intravaginaliai
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
BRPI0821029A2 (pt) 2007-12-20 2015-06-16 Merck Serono Sa Fomulações de peg-interferon-beta
EA201590790A1 (ru) 2012-10-26 2015-08-31 Люпин Лимитед СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
WO2016046101A1 (en) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
ZA9610374B (en) * 1995-12-11 1997-06-23 Elan Med Tech Cartridge-based drug delivery device
KR20000069664A (ko) * 1996-12-24 2000-11-25 아스트루 마이클 제이 안정한 액체 인터페론 제제
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
JP4574007B2 (ja) 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム ポリオール−ｉｆｎ−ベータ複体
SK287758B6 (sk) * 1998-05-11 2011-09-05 Basf Aktiengesellschaft Oxímy a ich použitie na prípravu izoxazolin-3-yl-acylbenzénov
CN1175901C (zh) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
CA2547822A1 (en) * 2003-12-11 2005-06-30 Ares Trading S.A. Stabilized interferon liquid formulations
JP2007538048A (ja) * 2004-05-17 2007-12-27 アレス トレーディング ソシエテ アノニム ヒドロゲル・インターフェロン製剤
WO2005117948A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins

Also Published As

Publication number Publication date
AU2009201261A1 (en) 2009-04-23
JP4870550B2 (ja) 2012-02-08
EP1617861A2 (en) 2006-01-25
AR044147A1 (es) 2005-08-24
JP5346065B2 (ja) 2013-11-20
BRPI0410488B8 (pt) 2021-09-08
EA200800327A1 (ru) 2008-10-30
NO335674B1 (no) 2015-01-19
MY151121A (en) 2014-04-30
EP1617861B1 (en) 2013-05-29
TW200503754A (en) 2005-02-01
NZ542912A (en) 2008-04-30
ES2417061T3 (es) 2013-08-05
WO2004096263A2 (en) 2004-11-11
WO2004096263A3 (en) 2004-12-02
ZA200508124B (en) 2009-02-25
PT1617861E (pt) 2013-08-28
MXPA05011718A (es) 2006-01-23
ZA200708484B (en) 2008-10-29
JP2006525280A (ja) 2006-11-09
RS20050821A (en) 2007-12-31
HK1088847A1 (en) 2006-11-17
NZ566625A (en) 2010-02-26
BRPI0410488A (pt) 2006-06-13
UA94032C2 (ru) 2011-04-11
TWI272948B (en) 2007-02-11
KR101116058B1 (ko) 2012-04-12
EA009995B1 (ru) 2008-06-30
US20070059285A1 (en) 2007-03-15
RS52869B (sr) 2013-12-31
IL171709A (en) 2016-03-31
BRPI0410488B1 (pt) 2021-06-22
AU2004233603B2 (en) 2009-02-26
NO20055666L (no) 2005-11-30
MEP60408A (en) 2011-05-10
HRP20130512T1 (hr) 2013-07-31
KR20060011976A (ko) 2006-02-06
SI1617861T1 (sl) 2013-09-30
CA2521560A1 (en) 2004-11-11
JP2011225599A (ja) 2011-11-10
PL1617861T3 (pl) 2013-10-31
DK1617861T3 (da) 2013-07-29
UA80331C2 (en) 2007-09-10
AU2004233603A1 (en) 2004-11-11
CN1816347A (zh) 2006-08-09
SG159389A1 (en) 2010-03-30
US8309069B2 (en) 2012-11-13
ME00404B (me) 2011-10-10
CN1816347B (zh) 2010-07-21

Similar Documents

Publication Publication Date Title
EA200501699A1 (ru) Стабилизированные жидкие композиции интерферона, не содержащие человеческий сывороточный альбумин
EA200602257A1 (ru) Стабилизированные жидкие препаративные формы интерферона
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
EA200602254A1 (ru) Способ стабилизации белков
EA200602137A1 (ru) Гидрогелевые препараты интерферона
DE60224284D1 (de) Stabile formulierung von modifiziertem glp-1
AR007051A1 (es) Una composicion farmaceutica y el uso de una combinacion sinergica de interleucina-12 (il-12) e interferon-alfa (ifn alfa)
WO2003028757A1 (fr) Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
CY1112193T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης
MXPA05009135A (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
HUP0303309A2 (hu) Csökkentett immunogenitású módosított interferon-alfa
TR200003521T2 (tr) Yeniden-kombine-edilen insan interferonu beta-1a (IFN-beta-1a) formülasyonu.
ATE253938T1 (de) Pharmazeutische kombination von antiviralen wirkstoffen
ITRM20010336A1 (it) Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
DE60134883D1 (de) Interferon- und interleukin-derivate mit langzeitwirkung und diese enthaltende pharmazeutische zusammensetzungen
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
PT1448219E (pt) Agente antiglaucomatoso e sua utilizacao
CY1108402T1 (el) Φαρμακευτικο μεσο που περιεχει μια αντιφλεγμονωδη δραστικη ουσια και υδρολυμα λακταλβουμινης και χρηση αυτου
FR2834894B1 (fr) Composition pharmaceutique orodispersible de piribedil
NO20065853L (no) Hydrogelinterferonformuleringer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM